Profilo
Manuel Opitz is the founder of Mecuris GmbH, founded in 2016, where he holds the title of Expert Digital Transformation.
He is also the founder of deepeye Medical GmbH, founded in 2021, where he currently holds the title of Chief Executive Officer.
Posizioni attive di Manuel Opitz
| Società | Posizione | Inizio |
|---|---|---|
Mecuris GmbH
 Mecuris GmbH Commercial Printing/FormsCommercial Services Mecuris GmbH operates a software platform for automatic generation of patient-customized orthoses and prosthetic designs. The company was founded by Manuel Opitz, Wolf-Peter Werner, Felix Gundlack, Jannis Breuninger and Simon Weidert and is headquartered in Munich, Germany. | Fondatore | 22/06/2016 |
Deepeye Medical GmbH
 Deepeye Medical GmbH Information Technology ServicesTechnology Services Deepeye Medical GmbH is a German medical company that aims to address the issue of millions going blind every year despite effective retinal therapy. The private company is located in Germany. The company's co-founders have developed a 2nd-opinion-approach using AI to scale their solution. The company also offers Deepeye® research, which unlocks the future of clinical studies. | Amministratore Delegato | 01/01/2021 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Mecuris GmbH
Mecuris GmbH Commercial Printing/FormsCommercial Services Mecuris GmbH operates a software platform for automatic generation of patient-customized orthoses and prosthetic designs. The company was founded by Manuel Opitz, Wolf-Peter Werner, Felix Gundlack, Jannis Breuninger and Simon Weidert and is headquartered in Munich, Germany. | Commercial Services |
Deepeye Medical GmbH
Deepeye Medical GmbH Information Technology ServicesTechnology Services Deepeye Medical GmbH is a German medical company that aims to address the issue of millions going blind every year despite effective retinal therapy. The private company is located in Germany. The company's co-founders have developed a 2nd-opinion-approach using AI to scale their solution. The company also offers Deepeye® research, which unlocks the future of clinical studies. | Technology Services |
- Borsa valori
- Insiders
- Manuel Opitz
